24-Valent Pneumococcal Conjugate Vaccine Designed to Deliver Broad-Spectrum Protection Doses 1st Patient
California-based Vaxcyte, Inc. recently announced that the first participants were dosed in the Phase 1/2 clinical study of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD) and pneumonia in adults.
VAX-24 is intended to improve upon the standard-of-care PCV vaccines for both children and adults by covering the serotypes responsible for most of the residual pneumococcal disease currently in circulation.
With VAX-24, Vaxcyte expects to add more pneumococcal strains without compromising the overall immune response.
Grant Pickering, CEO and Co-founder of Vaxcyte, commented in a press release issued on Feb. 23, 2022, "We developed VAX-24, using advanced chemistry and our novel XpressCFTM platform, with the intent to deliver the broadest spectrum PCV to effectively prevent pneumococcal disease."
"We look forward to announcing the topline safety, tolerability, and immunogenicity result from this clinical study by the end of the year."
For more information, visit www.vaxcyte.com.
Pneumococcal disease is an infection caused by Streptococcus pneumoniae bacteria.
It can result in IPD, including meningitis and bacteremia, and non-invasive PD, including pneumonia, otitis media, and sinusitis, says the U.S. CDC.
Pneumococcal vaccine news is posted on this Precision Vaccinations webpage.